Scinovex
articleTop 1% cited

Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study

Alimentary Pharmacology & Therapeutics · 2001 · Vol. 15(10) · pp. 1667–1672
Tsukasa HasegawaMasashi YonedaKimihide NakamuraIsao MakinoAkira Terano

Abstract

Our data suggest that the measurement of the level of plasma transforming growth factor-beta1 represents a possible method of distinguishing between non-alcoholic steatohepatitis and non-alcoholic fatty liver. Long-term alpha-tocopherol treatment may be safe and effective for non-alcoholic steatohepatitis. A randomized, controlled, double-blind trial is needed to confirm the full potential of alpha-tocopherol in the management of non-alcoholic steatohepatitis.

Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver physiology and pathologySteatohepatitisMedicineAlcoholic hepatitisFatty liverInternal medicineGastroenterologyAlcoholic liver diseaseCirrhosisAlanine transaminaseFibrosis

MeSH terms

AdultAlanine TransaminaseAlkaline PhosphataseAspartate AminotransferasesBody WeightCholesterolFatty LiverFemalegamma-GlutamyltransferaseHepatitisHumansLiver CirrhosisMalePilot ProjectsTriglycerides

Funding

  • Smoking Research Foundation
Citations
406
FWCI
14.63
field-weighted impact
References
33
Percentile
99%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study · Scinovex